Next Article in Journal
Meta-Analysis on Associations of RGS1 and IL12A Polymorphisms with Celiac Disease Risk
Next Article in Special Issue
Aneurysmal Subarachnoid Hemorrhage and Neuroinflammation: A Comprehensive Review
Previous Article in Journal
Restricted Gene Flow for Gadus macrocephalus from Yellow Sea Based on Microsatellite Markers: Geographic Block of Tsushima Current
Previous Article in Special Issue
Long-Term Treatment with Citicoline Prevents Cognitive Decline and Predicts a Better Quality of Life after a First Ischemic Stroke
Article

Exploring Erythropoietin and G-CSF Combination Therapy in Chronic Stroke Patients

by 1,2 and 1,2,3,4,*
1
Department and Research Institute of Rehabilitation Medicine, Yonsei University College of Medicine, Seoul 03722, Korea
2
Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 03722, Korea
3
Rehabilitation Institute of Neuromuscular Disease, Yonsei University College of Medicine, Seoul 03722, Korea
4
Yonsei Stem Cell Research Center, Avison Biomedical Research Center, Seoul 03722, Korea
*
Author to whom correspondence should be addressed.
Academic Editors: Katalin Prokai-Tatrai and Cesar Borlongan
Int. J. Mol. Sci. 2016, 17(4), 463; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms17040463
Received: 31 December 2015 / Revised: 10 March 2016 / Accepted: 23 March 2016 / Published: 30 March 2016
(This article belongs to the Special Issue Neuroprotective Strategies 2016)
Erythropoietin (EPO) and granulocyte-colony stimulating factor (G-CSF) are known to have neuroprotective actions. Based on previous reports showing the synergistic effects of EPO+G-CSF combination therapy in experimental models, we investigated the safety of EPO+G-CSF combination therapy in patients with chronic stroke. In a pilot study, 3 patients were treated with EPO and G-CSF for 5 consecutive days, with follow-up on day 30. In an exploratory double-blind study, 6 patients were allocated to treatment with either EPO+G-CSF or placebo. Treatment was applied once a day for 5 days per month over 3 months. Participants were followed up for 6 months. To substantiate safety, vital signs, adverse events, and hematological values were measured on days 0, 5, and 30 in each cycle and on day 180. Functional outcomes were determined on day 0 and 180. In the laboratory measurements, EPO+G-CSF combination therapy significantly elevated erythropoietin, CD34+ hematopoietic stem cells, white blood cells, and neutrophils on day 5 of each cycle. There were no observations of serious adverse events. In the functional outcomes, the grip power of the dominant hand was increased in the EPO+G-CSF treatment group. In conclusion, this exploratory study suggests a novel strategy of EPO+G-CSF combination therapy for stroke patients. View Full-Text
Keywords: erythropoietin; granulocyte-colony stimulating factor; combination therapy; stroke; neuroprotection erythropoietin; granulocyte-colony stimulating factor; combination therapy; stroke; neuroprotection
Show Figures

Graphical abstract

MDPI and ACS Style

Shin, Y.-K.; Cho, S.-R. Exploring Erythropoietin and G-CSF Combination Therapy in Chronic Stroke Patients. Int. J. Mol. Sci. 2016, 17, 463. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms17040463

AMA Style

Shin Y-K, Cho S-R. Exploring Erythropoietin and G-CSF Combination Therapy in Chronic Stroke Patients. International Journal of Molecular Sciences. 2016; 17(4):463. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms17040463

Chicago/Turabian Style

Shin, Yoon-Kyum, and Sung-Rae Cho. 2016. "Exploring Erythropoietin and G-CSF Combination Therapy in Chronic Stroke Patients" International Journal of Molecular Sciences 17, no. 4: 463. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms17040463

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop